Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses

Antimicrobial Agents and Chemotherapy
Frank P TverdekDimitrios P Kontoyiannis

Abstract

Posaconazole is the preferred mold-active azole for prophylaxis against invasive fungal infections (IFIs) in patients with hematological malignancy. Delayed-release tablet and intravenous formulations of posaconazole have recently become available, but clinical data are limited. We sought to examine the real-world pharmacokinetics and prophylactic effectiveness of the new formulations of posaconazole given as prophylaxis for patients with hematological malignancy. A retrospective cohort of all consecutive adult inpatients with hematological malignancy who received ≥3 days of tablet or intravenous posaconazole therapy for primary IFI prophylaxis at the M. D. Anderson Cancer Center between 1 December 2013 and 31 December 2015 was established. Clinical information was collected and correlated with low posaconazole serum levels (<700 ng/ml). Rates of IFIs and safety events were assessed. A total of 1,321 courses of posaconazole were administered at the M. D. Anderson Cancer Center during the study period, of which 343 courses were assessed for prophylactic safety and effectiveness. Seventy-nine patients (23%) had posaconazole serum level measurements available for interpretation. Acute myeloid leukemia was the primary malignancy (6...Continue Reading

References

Jan 26, 2007·The New England Journal of Medicine·Oliver A CornelyDavid Angulo-Gonzalez
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ben De PauwUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Oct 24, 2008·The New England Journal of Medicine·Pierre-Yves BochudMichael Boeckh
Apr 20, 2011·Antimicrobial Agents and Chemotherapy·Werner J HeinzHartwig Klinker
Mar 7, 2012·Antimicrobial Agents and Chemotherapy·Michael J DoltonAndrew J McLachlan
Jul 4, 2012·Antimicrobial Agents and Chemotherapy·Michael J DoltonAndrew J McLachlan
Aug 15, 2012·Antimicrobial Agents and Chemotherapy·Michael J DoltonAndrew J McLachlan
Jan 1, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L Pagano, M Caira
Sep 4, 2014·Antimicrobial Agents and Chemotherapy·Russell E LewisDimitrios P Kontoyiannis
Jun 10, 2015·Antimicrobial Agents and Chemotherapy·Urshila DuraniAaron J Tande
Nov 26, 2015·The American Journal of Medicine·Vincent Lo ReDouglas A Corley
Nov 28, 2015·The Journal of Antimicrobial Chemotherapy·Oliver A CornelyHetty Waskin
Jun 9, 2016·Expert Review of Anti-infective Therapy·Frank P TverdekDimitrios P Kontoyiannis

❮ Previous
Next ❯

Citations

Mar 21, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Caitlin R Rausch, Dimitrios P Kontoyiannis
May 18, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Caitlin R RauschDimitrios P Kontoyiannis
May 8, 2018·Antimicrobial Agents and Chemotherapy·David AndesThomas J Walsh
Jun 4, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michail S LionakisDimitrios P Kontoyiannis
Feb 26, 2019·Antimicrobial Agents and Chemotherapy·Mathew J MasonDimitrios P Kontoyiannis
Jun 25, 2019·Medical Mycology·Ana Fernández-CruzPatricia Muñoz
Oct 30, 2019·Mycoses·Alexander F A D SchauwvliegheRoger J M Brüggemann
Jul 31, 2019·Antimicrobial Agents and Chemotherapy·Elodie Gautier-VeyretFrançoise Stanke-Labesque
Jun 2, 2020·Expert Opinion on Drug Metabolism & Toxicology·Ruth Van DaeleJohan Maertens
Apr 3, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Prithviraj BoseDimitrios P Kontoyiannis
Jun 28, 2019·Frontiers in Pharmacology·Tim BühlerAnne Leuppi-Taegtmeyer
Jan 16, 2020·Mycopathologia·Anastasia WasylyshynMarisa H Miceli
Dec 14, 2018·Journal of Fungi·Nikolaos Spernovasilis, Diamantis P Kofteridis
Jan 4, 2020·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Erika N WassCaroline M Sierra
Apr 24, 2020·Drugs·Lu ChenRoger J M Brüggemann
Mar 27, 2019·Antimicrobial Agents and Chemotherapy·Frederic RiesMarkus Philipp Radsak
Apr 2, 2021·The Journal of Infection·Peijun Yvonne ZhouLay Hoon Andrea Kwa
Apr 23, 2021·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Emily A HighsmithTodd W Canada
May 22, 2021·Infectious Disease Clinics of North America·Jose CadenaThomas F Patterson
May 22, 2021·Infectious Disease Clinics of North America·Julie M Steinbrink, Marisa H Miceli
May 28, 2021·Current Opinion in Infectious Diseases·Julien CoussementMonica Slavin
Jul 31, 2021·Expert Review of Anti-infective Therapy·Daniel Echeverria-EsnalSantiago Grau
May 18, 2021·Revista iberoamericana de micología·Carolina García-VidalIsidro Jarque
Nov 12, 2021·Expert Opinion on Pharmacotherapy·Paraskevi Panagopoulou, Emmanuel Roilides
Sep 28, 2021·Antimicrobial Agents and Chemotherapy·Adam J DiPippoDimitrios P Kontoyiannis
Dec 23, 2021·Internal Medicine Journal·Olivia Bupha-IntrUNKNOWN Australasian Antifungal Guidelines Steering Committee
Dec 23, 2021·Internal Medicine Journal·Benjamin W TehUNKNOWN Australasian Antifungal Guidelines Steering Committee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.